FORM PTO-1083

COMMISSIONER FOR PATENTS

P.O Box 1450

Alexandria, VA 22313-1450



Docket No.: 200.1102CON3

Date: ___July 1, 2004

In re application of:

Robert F. KAIKO, et al.

Serial No.:

10/694,559

Filed:

October 27, 2003

For:

OPIOID AGONIST/ANTAGONIST COMBINATIONS

Sir:

Transmitted herewith is an Information Disclosure Statement in the above-identified application.

Small entity status of this application under 37 C.F.R. 1.9 and 1.27 has been established by a verified statement previously submitted.

A verified statement to establish small entity status under 37 C.F.R. 1.9 and 1.27 is enclosed.

No fee for additional claims is required.

A filing fee for additional claims calculated as shown below, is required:

Col. FOR: REMAIN AFTER	PREVIOUSLY	PRESENT	SMALL ENTITY RATE FEE	<u>OR</u>	LARGE ENTITY RATE FEE
	Minus 20** =	EXTRA 0 P. CLAIM	x \$ 9 \$		x \$ 18 \$ x \$ 84 \$ + \$280 \$
		•	TOTAL: \$	OR	

If the entry in Co. 1 is less than the entry in Col. 2, write "0" in Col. 3.

If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, write "20" in this space.

If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, write "3" in this space.

[X]	Also	transmitted	herewith	are:
			TICIC VALUE	ale

[] Petition for extension under 37 C.F.R. 1.136 (in duplicate)

[X] Other: PTO form 1449 (24 pages).

Check(s) in the amount of \$.00 is/are attached to cover:

[] Filing fee for additional claims under 37 C.F.R. 1.16

Petition fee for extension under 37 C.F.R. 1.136

[] Other:

The Assistant Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 50-0552.

Any filing fee under 37 C.F.R. 1.16 for the presentation of additional claims which are not paid by check submitted herewith.

Any patent application processing fees under 37 C.F.R. 1.17.

Any petition fees for extension under 37 C.F.R. 1.136 which are not paid by check submitted herewith, and it is hereby requested that this be a petition for an automatic extension of time under 37 CFR

Repert J. Paradiso, Reg. No. 41,240 DAVIDSON, DAVIDSON & KAPPEL, LLC

485 Seventh Avenue, 14th Floor New York, New York 10018

Tel: (212) 736-1940 Fax: (212) 736-2427

ereby certify that this correspondence and/or documents referred to as attached therein id/or fee are being deposited "via hand delivery" in an envelope addressed to ommissioner for Patents, P.O. Box 1450, Alexandria, A 22313-1450". on July

UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner: To be determined; Art Unit: 1615

Re:

Application of:

Robert F. KAIKO et al.

Serial No.:

10/694,559

Filed:

October 27, 2003

For:

OPIOID AGONIST/ANTAGONIST COMBINATIONS

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.56

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 July 1, 2004

Sir:

In accordance with the provisions of 37 C.F.R. § 1.97, Applicants hereby make of record the documents listed on the accompanying Form PTO-1449 (24 sheets) for consideration by the Examiner in connection with the examination of the above-identified patent application.

Pursuant to 37 C.F.R. § 1.98 (a), the foreign patent documents and non-patent references listed on sheets 1-24 of the attached Form PTO-1449 are enclosed. If it is determined that any of the listed references are not of record in the parent application or presently enclosed, the Examiner is requested to contact the undersigned so that a copy can be forwarded.

Applicants also respectfully advise the Examiner of the following U.S. Patents and copending U.S. Patent Applications which are commonly assigned to the owners of the instant application:

U.S. Application Serial No. 09/992,936, entitled "Opiod Agonist/Opioid Antagonist Acetaminophen Combination", filed November 5, 2001, which is a continuation of U.S. Application Serial No. 09/503,020 filed February 11, 2000 entitled "Opioid Agonist/Opioid Antagonist/Acetaminophen Combinations", now U.S. Patent No. 6,375,957, issued April 23,

2002, which is a continuation in part of U.S. Application Serial No. 09/218,662, "Opioid Agonist/Antagonist Combinations", filed December 22, 1998, now U.S. Patent No. 6,277,384, issued August 21, 2001, listed as reference WG on the attached Form PTO-1449;

- U.S. Application Serial No. 10/665,735, entitled "A Method of Preventing Abuse of Opioid Dosage Forms", filed September 18, 2003, which is a continuation of U.S. Application Serial No. 09/815,162, now U.S. Patent No. 6,627,635, issued September 30, 2003, listed as reference XI on the attached Form PTO-1449;
- U.S. Application Serial No. 10/747,865, entitled "Controlled Release Compositions Containing Opioid Agonist and Antagonist", filed December 29, 2003, which is a continuation of U.S. Application Serial No. 09/781,076, now U.S. Patent No. 6,716,449, issued April 6, 2004, listed as reference XJ on the attached Form PTO-1449;
- U.S. Application Serial No. 10/689,866 filed October 21, 2003; 10/701,041 filed November 4, 2003; 10/700,861 filed November 4, 2003; 10/700,893 filed November 4, 2003; and 10/700,906 filed November 4, 2003, which are all continuations of U.S. Application Serial No. 09/781,081, entitled "Tamper-Resistant Oral Opioid Agonist Formulations", now U.S. Patent No. 6,696,088, issued February 24, 2004; listed as reference XK on the attached Form PTO-1449.
- U.S. Application Serial No. 10/213,919, entitled "Opioid Agonist Formulations with Releasable and Sequestered Antagonist", filed August 6, 2002;
- U.S. Application Serial No. 10/389,238, entitled "Naltrexone Hydrochloride Compositions", filed March 14, 2003;
- U.S. Application Serial No. 10/214,408, entitled "Sequestered Antagonist Formulations", filed August 6, 2002; and
 - U.S. Application Serial No. 10/199,972, entitled "Pharmaceutical Combinations of

Oxycodone and Naloxone", filed July 18, 2002.

Pursuant to 37 C.F.R. § 1.98 (a)(2)(iii), the Examiner's attention is directed to **Exhibit A**, attached herewith, which contains the following:

- (i) the claims of pending U.S. Application Serial No. 09/992,936, which has the same specification as U.S. Patent No. 6,375,957, listed as reference XE on the attached Form PTO-1449;
- (ii) the claims of pending U.S. Application Serial No. 10/665,735, which has the same specification as U.S. Patent No. 6,627,635, listed as reference XI on the attached Form PTO-1449;
- (iii) the claims of pending U.S. Application Serial No. 10/747,865, which has the same specification as U.S. Patent No. 6,716,449, listed as reference XJ on the attached Form PTO-1449;
- (iv) the claims of pending U.S. Application Serial Nos. 10/689,866; 10/701,041; 10/700,861; 10/700,893; and 10/700,906, which have the same specification as U.S. Patent No. 6,696,088, listed as reference XK on the attached Form PTO-1449; and
- (v) the specifications and claims for pending U.S. Applications Serial Nos. 10/213,919, 10/214,408, 10/389,238 and 10/199,972.

It is respectfully requested that the references cited in the accompanying Form PTO-1449 (24 sheets) be considered and made of record.

This Information Disclosure Statement is filed under 37 C.F.R. § 1.97 (b), before the mailing of a first Office Action on the merits. Accordingly, no fee is believed due. In the event any additional fee is due or any overpayment made in connection with the filing of this Information Disclosure Statement, the Commissioner is hereby authorized to charge said deficiency or credit overpayment to our Deposit Account No. 50-0552.

Respectfully submitted,

DAVIDSON, DAVIDSON & KAPPEL, LLC

By Robert I Paradis

Reg. No. 41,240

Davidson, Davidson & Kappel, LLC 485 Seventh Avenue, 14th Floor New York, New York 10018 (212) 736-1940

JUL 0 6 2004 3

FORM	PT	0-1	449
/RFV	7_8	O١	

PADEMARY S.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.: 200.1102CON3

SERIAL NO.: 10/694,559

	LIST	OF PI	RIOR	ART (CITED	BY A	PPLIC	CANT		APPLICANT(S): Robert F. KAIKO et al.				
	(Use s	several s	heets i	f necess	sary)					FILING DATE: October 27, 2003		GROUP: 1615		
								U.	S. PATENT DOC	CUMENTS				
*EXAMINER INITIAL		DOC	:UMEN	T NUME	3ER				DATE	NAME	CLASS	SUBCLASS	FILING DATE	
	AA	2	7	7	0	5_	6	9	11/56	Fromherz et al.	167	65		
	AB	3	1	3	3	1	3	2	05/12/64	Loeb, et al.	264	49		
	AC	3	1	7	3	8	7	6	03/16/65	Zobrist	252	137		
	AD	3	2	7	6	5	8	6	10/04/66	Rosaen	210	90		
	AE	3	3	3	2	9	5	0_	7/67	Blumberg et al.	260	285		
	AF	3	4	9	3	6	5	7	2/70	Lewenstein et al.	424	260		
	AG	3	6	7	6	5	5	7	7/72	Lachman et al.	424	260		<u> </u>
	AH	3	7	7	3	9	5	5	11/73	Pachter et al.	424	260		
	Al	3	8	7	9	5	5	5	4/75	Pachter et al.	424	260	<u> </u>	
								FOR	EIGN PATENT D	OCUMENTS			,	
		DOC	UMEN	IT NUM	3ER				DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATIO	ON
													YES	NO
	AJ	8	3	0	3	1	9	7	9/83	wo	A61K	9/22		
	AK	9	0	0	4	9	6	5	05/17/1990	wo	A61K	31/485	ļ <u>.</u>	<u> </u>
	AL	9	4	0	6	4	2	6	3/94	wo	A61K	31/46		<u> </u>
	AM	9	5	0	3	8	0	4	2/95	wo	A61K	31/485	ļ <u>.</u>	ļ
	AN	9	6	0	2	2_	5	1	2/96	wo	A61K	31/485		
					01	THER F	RIOR /	ART (In	cluding Author, T	Fitle, Date, Pertinent Pages	i, Etc.)		,	
	AO	Foss Mon	s, J.F., e phine",(et al.Abs Cancer	stract, " Chemot	Prevent	tion of A	Apomorj I (1998)	phine- or Cisplati ; 42(4):287-91.	in- induced emesis in the d	og by combina	ition of Methylnaltre	xone and	
	AP			"Efficac ce (1998			ninister	ed Meth	hylnaltrexone in (Decreasing Subjective Effe	cts After Intrav	enous Morphine",D	rug and Alcohol	
	AQ	Gan 1080		'Opioid-	Sparing	j Effects	s of a Lo	ow-Dos	e Infusion of Nal	oxone in Patient-Administe	red Morphine	Sulfate," Anesthesio	ology (1997), 87(5	5):1075-
	AR			, "Ultra-L n Resea					torphine Increase	e Morphine's Antinociecept	live Potencey a	and Attenuate Tolera	ance/Dependenc	e in
	AS	Yuai	n et al.,		afety an	nd Effica	acy of C		hylnaltrexone in	Preventing Morphine-induc	ced Delay in O	ral-Cecal Transit Tir	ne", Clinical Trial	ls and
	AT							Naloxor	ne Interactions in	Opiate Dependent Volunte	eers," Clin. Ph	ar. Ther. (1996), 60:	105-114.	
	AU								<u>.</u>	Cocain, Hydromorphone ar				
FYAMINER										DATE CONSIDERED				

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-144 (REV. 7-80)	9							_	F COMMERCE MARK OFFICE	ATTY, DOCKET NO 200.1102CON3).:	SERIAL NO.: 10/694,559		
		OF P				BY A	PPLIC	CANT		APPLICANT(S): Robert F. KAIKO et	al.			
	(Use s	several s	sheets	f neces	sary)					FILING DATE: October 27, 2003		GROUP: 1615		
								U.	S. PATENT DOC	UMENTS				
EXAMINER NITIAL		DOC	UMEN	T NUM	BER	_	,		DATE	NAME	CLASS	SUBCLASS	FILING DA	
	ВА	3	9	1	6	8	8	9	11/04/1975	Russell	128	145.8		
	BB	3	9	6	5	2	5	6	06/22/1976	Leslie	424	22		
	ВС	3	9	6	6	9	4	0_	6/76	Pachter et al.	424	260		
	BD	4	1	7	6	1	8	6_	11/79_	Goldberg	424	260		
	BE	4	2	3	7	1	4	0	12/02/1980	Dudzinski	424	260		
								FOR	EIGN PATENT D	OCUMENTS	_			
		DOC	UMEN	T NUM	BER				DATE	COUNTRY	CLASS	SUBCLASS	TRANSLA	TION
													YES	МО
	BF	9	7	3	3	5	6	6	9/97	wo	A61K	9/20		
	BG	9	8	3	5	6	7	9	8/98	wo	A61K	31/485		
	ВН	9	9	3	2	1	2	0	7/99	wo	A61K	31/485		
	ВІ	0	0	0	1	3	7	7	01/13/2000	wo	A61K	31/00		
	ВЈ	8	7	0	1	2	8	2	03/12/1987	wo	A61K	31/485		
					01	THER P	RIOR A	NRT (Inc	cluding Author, T	itle, Date, Pertinent Pa	ges, Etc.)			
	ВК	Chih	-Cheng	Chien,	et al., "	Sigma /	Antagor	nists Po	tentiate Opioid A	nalgesia in Rats", Neu	roscience Letters	190 (1995), 137-13	9.	
	BL	Crair	n et al.,	"Ultra-L	ow Cor	centrat	ions of	Naloxo	ne Selectively Ar	ntagonize Excitory Effe	cts of Morphine or	Sensory Neurons	Thereby Incre	
	BN	Hans	son, An	algesic,	, Antipyi	etic and	d Anti-Ir	nflamma	atory Drugs in Re	emington's Science and	Practice of Phan	macy (1995), 2:120	7.	
	во	Talw	in NX,	Physicia	an's De	sk Refe	rence 4	8 th Ed.	(1994) Montvale,	NJ 2120-2121.				
	ВР									ohine by Methylnaltrex	one in Dogs",J. Cl	in Pharmacol (1993	3), 33:747-751	
	BQ	Holm	nes et a	l., "Inhil	biting S	oinal Dy	norphir	A Con	nponent Enhance	es Intrathecal Morphine	Antinocicption in	Mice", Anesth. Ana	alg. (1993), 77:	1166-73.
	BR								<u>-</u>	oinal Administration of				
EXAMINER										DATE CONSIDERE	D			

FORM PTO-1449 (REV. 7-80)									COMMERCE MARK OFFICE	ATTY. DOCKET NO.: 200.1102CON3		SERIAL NO.: 10/694,559		
	LIST	OF PI	RIOR	ART (CITED	BY A	PPLIC	ANT		APPLICANT(S): Robert F. KAIKO et al.				
	(Use s	everal s	heets i	fneces	sary)					FILING DATE: October 27, 2003		GROUP: 1615		
								U.	S. PATENT DOC	UMENTS				
*EXAMINER INITIAL		DOC	UMEN	T NUME	BER				DATE	NAME	CLASS	SUBCLASS	FILING DATE	
	CA	4	2	8	5	9	8	7	08/25/1981	Ayer, et al.	427	3		
	СВ	4	3	6	6	3	1	0	12/28/1982	Leslie	536	56		
	СС	4	4	0	1	6	7	2	8/83	Portoghese et al.	424	260		
	CD	4	4	4	3	4	2	8	04/17/1984	Oshlack et al.	424	22		
	CE	4	4	5	1	4	7	0	5/84	Ganti	424	260		
	CF	4	4	5	7	9	3	3	7/84	Gordon et al.	424	260		
	CG	4	4	6	4	3	7	8	8/84	Hussain et al.	424	260		
								FORE	EIGN PATENT D	OCUMENTS			•	
		DOC	UMEN	T NUM	BER				DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATIO	N
													YES	NO
	СН	0	1	3	2	1	8	0	05/10/2001	WO (A2)	A61K	31/485		
	CI	0_	1	6	8	0	8	0	09/20/2001	WO (A2)	A61K	31/00		
	CJ	0	1	3	7	7	8	5	05/31/2001	WO (A2)	A61K			
	СК	0	1	5	2	8	5	1	07/26/2001	WO (A1)	A61K	31/485		
	CL	0_	1	8	5	2	5	7	11/15/2001	WO (A2)	A61P			
					07	THER P	RIOR A	ART (Inc	cluding Author, T	itle, Date, Pertinent Pages	, Etc.)			
	СМ	Weir 274.	nhold et	al., "Bu	prenor	ohine A	lone an	d in Co	mbination with N	altrexone in Non-Depende	nt Humans," Da	ug and Alcohol De	pendence (1992)	, 30:263-
	CN	Сар	oel et al	., "Enha	anceme	nt of Na	aloxone	Induce	d Analgesia by P	retreatment with Morphine	" Pharma. Biod	h. & Behav. (1989)	, 34:425-427.	
	со									Antagonists Alone and in (09.
	СР				altrexon s (1988			its Pha	rmacodynamic a	nd Pharmacokinetic Prope	rties and Thera	speutic Efficacy in t	he Management	of Opioid
	CQ		shine, e					entazoc	ine Versus a Per	tazocine-Naloxone Combi	nation Followin	g Oral Administrati	on," Clin. J. Pain	(1988),
	CR	Wan	g et al.,	"Cross	over an	d Paral	lel Stud	y of Ora	al Analgesics," J.	Clin. Pharmacol (1981), 2	1:162-168.			
	cs				nan pat									
EXAMINER										DATE CONSIDERED				
*EXAMINER: Initia						ot citatio	on is in o	conform	nance with MPEF	609; Draw line through cit	tation if not in c	onformance and no	ot considered. In	clude

FORM PTO-1449 (REV. 7-80)									COMMERCE MARK OFFICE	ATTY. DOCKET NO.: 200.1102CON3		SERIAL NO.: 10/694,559		
	LIST	OF PI	RIOR	ART (ITED	BY A	PPLIC	CANT		APPLICANT(S): Robert F. KAIKO et al.				
	(Use s	everal s	heets i	f neces	sary)					FILING DATE: October 27, 2003		GROUP: 1615		
					·			U.	S. PATENT DOC	CUMENTS			_	
*EXAMINER INITIAL		DOC	UMEN	T NUME	BER				DATE	NAME	CLASS	SUBCLASS	FILING DA	
	DA	4	5	7	3	9	9	5	3/86	Chen et al.	604	896		
	DB	4	5	8	2	8	3	5	4/86	Lewis et al.	514	282		
	DC	4	6	0	8	3	7	6	8/86	Pastemak	514	282		
	DD	4	6	6	1	4	9	2	4/87	Lewis et al.	514	282		
	DE	4	7	1	9	2	1	5	1/88	Goldberg	514	282		
	DF	4	7	3	0	0	4	8	3/88	Portoghese et al.	546	45		
	DG	4	7	6	0	0	6	9	7/88	Rzeszotarski et al.	514	282		
		<u> </u>	<u></u>			<u> </u>			EIGN PATENT D		1		•	
	-	DOC	UMEN	T NUMI	BER			1014	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLA	TION
													YES	NO
	DH	0 -	1	9	3	8	5	2	12/31/2001	WO (A2)	A61K	31/00		
	DI	0	9	1	3	1_	5	2	6/99	EP	A61K	31/485		
	DJ	0	6	4	7	4_	4	8	4/95	EP	A61K	31/485	ļ	
	DK	0	3	5	2	3	6	1	1/90	EP	A61K	31/485		
	DL	0	2	0	5	2	8	2	12/86	EP	A61K	9/22		
					01	THER P	RIOR A	ART (In	cluding Author, T	itle, Date, Pertinent Pages	s, Etc.)			_
	DM			entes, e	al. "Eff	ectiven	ess of F			of a New Ora Naltrexone		ease System in Mo	rphine Analges	sia"; J.
	DN							of an C	Oral Controlled R	elease Naltrexone Comple	x in Mice"; J. F	harm Pharmacol (2	2000), 52:659-	663.
	DO	1								velopment of Naltrexone";				
	DP									and Abuse of Pentazocine"				
	DQ	1								search Monograph 147 (19				
	DR	T	m et al.							o of 1:20"; 5 th National Co		ethadone Treatmen	t (1973) Vol 2,	p. 1342-
EXAMINER				· 						DATE CONSIDERED				
*EXAMINER: Initia						ot citation	on is in	conform	nance with MPEF	P 609; Draw line through ci	tation if not in o	conformance and no	ot considered.	Include

FORM PTO-1449 (REV. 7-80)	•				_				COMMERCE MARK OFFICE	ATTY. DOCKET NO.: 200.1102CON3		SERIAL NO.: 10/694,559		
	LIST	OF PI	RIOR	ART C	ITED	BY A	PPLIC	ANT		APPLICANT(S): Robert F. KAIKO et al.		- 1		
	(Use s	everal s	heets i	fnecess	sary)					FILING DATE: October 27, 2003		GROUP: 1615	-	
								U.	S. PATENT DOC	UMENTS				
*EXAMINER INITIAL		DOC	UMEN'	T NUME	BER				DATE	NAME	CLASS	SUBCLASS	FILING DATE	
	ĘΑ	4	7	6	9	3	7	2	9/88	Kreek et al.	514	282		
	EB	4	7	8	5	0	0	0	11/88	Kreek et al.	514	282		
	EC	4	8	0	3	2	0	8	2/89	Pasternak	514	282		-
	ED	4	8	0	6	3	4	1	2/89	Chien et al.	424	448		
	EE	4	8	0	6	5	4	3	2/89	Choi	514	464		
	EF	4	8	0	6	5	5	8	2/89	Wuest et al.	514	381		
	EG	4	8	2	8	8	3	6	05/09/1989	Elger et al.	424	419		
	I							FORE	IGN PATENT D					
		DOC	UMEN	T NUM	BER				DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATIO	ON .
													YES	NO
	EH	0	1	9	3	3	5	5	09/03/1986	EP (A3)	A61K	31/615		
	El	0	3_	1	9	2	4	3_	06/07/1989	EP (A1)	A61K	31/485		
	EJ	0	3	1	9	2	4	3	11/07/1990	EP (B1)	A61K	31/485		
	EK	19	6	5	1	5	5	1_1_	6/98	DE	A61K	31/485		
	EL	29	7	1	9	7	0	4	2/97	DE	A61K	31/485		
	_				01	HER P	RIOR A	NRT (Inc	cluding Author, T	itle, Date, Pertinent Pages	, Etc.)			
	ЕМ	Brisc	oe et a	I., "Metl	noclocir	inamox	Time (Course	of Changes in Al	fetnanil-Reinforced Rhesus	s Monkeys"; Ps	ychopharmacology	(2000) 148:393	-399.
	EN	Abst	ract of I	Bromm,	et al., "	A Sens	itive Me	ethod to	Evaluate Effects	of Analgesics in Man"; Me	th and Find Ex	ptl Clin Pharmacol	5 (8) (1983) p. 5	45-551.
	EO	Bullin	ngham	et al., "(Clinical	Pharam	cokine	ics of N	larcotic Agonist-	Antagonist Drugs"; Clinical	Pharm (1983)	8: 332-343.		
	EP	Calir		al. "Effe						ethadone in a 1:10 Oral Co			nere (1974) Vol.	15; No. 6
	EQ	Саги	so et a	I., "Meth	nadone	and Na	loxone	in Com	bination (Naldon	e®) for the Treatment if He	roin Addicts"; E	Bristol Laboratories,	pp.1336-1341F	
	ER	Cher	ny, Na	than I., '	'Opioid	Analge	sics"; D	rugs (1	996) May:51 (5)	op. 713-737.				
	ES	Chia	ng, et a	ıl. "Clini	cal Eva	luation	of a Nal	trexone	Sustained-Rele	ase Preparation"; Drug and	Alcohol Depe	ndence (1985) 16, j	op.1-8.	
EXAMINER										DATE CONSIDERED				
*EXAMINER: Initia						ot citatio	n is in o	conform	ance with MPEF	1 609; Draw line through cit	ation if not in c	onformance and no	t considered. In	clude

FORM PTO-1449 (REV. 7-80))								COMMERCE MARK OFFICE	ATTY. DOCKET NO.: 200.1102CON3		SERIAL NO.: 10/694,559		
	LIS	r of Pi	RIOR	ART (CITED	BY A	PPLIC	ANT		APPLICANT(S): Robert F. KAIKO et al.				
	(Use	several s	sheets if	neces	sary)					FILING DATE: October 27, 2003		GROUP: 1615	•	
								U.	S. PATENT DOC	CUMENTS				
*EXAMINER INITIAL		DOCU	IMENT I	NUMBI	ĒR				DATE	NAME	CLASS	SUBCLASS	FILING DATE	
	FA	4	8	3	4	9	6	5	05/30/7989	Martani et al.	424	488		
	FB	4	8	3	4	9	θ	4	05/30/1989	Goldie et al.	424	488		
	FC	4	8	3	4	9	6_	5	05/30/1989	Elger et al.	424	488		
	FD	4	8	4	4	9	0	7	07/04/1989	Elger et al.	424	465		
	FF	4	8	4	4	8	٥	9	07/04/1989	Goldie et al.	424	48C		
	FF	4	8	4	4	9	1	0	07/04/1989	Leslie et al.	424	494		
	FG	4	8	6	1	5	5	8	8/89	Oshlak et al.	424	468		
								FOR	IGN PATENT D	OCUMENTS		-		
		DOCU	JMENT I	NUMBI	ER				DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATIO	ON
													YES	NO
	FI	4		2	5	8	6	5	2/95	DE	A61K	31/485		х
, "	FI	2	2	2	2	0	3	9	11/72	DE	A61K	27/00		
	FJ	•	8	2	5	6	1	3	06/18/98	wo	A61K	31/485	abstract	
	FK	0	8	3	Ą	8	8		07/06/00	wo	A61K	9/00	abstract	
					0	THER F	RIOR	ART (Inc	cluding Author, T	itle, Date, Pertinent Pages	, Etc.)			
	FF	Chian	g et al.,	"Kineti	cs of a	Valtrex	ne Sus	tained-	Release Prepara	tion"; Clin Pharmacol Ther	a (1984) Vol 36	No. 5, pp.704-708		
	FM	Come	r et al., '	'Depot	Naltrex	one: Lo	ng-last	ng Anta	gonism of the E	fects Of Heroin un Human	s"; Psychophai	macology (2002) 1	59, pp.351-360.	
	FN	Crabtr	ree et al.	., "Revi	ew of N	laltrexo	ne, a lo	ng-actir	ng Opiate Antago	nist"; Clinical Pharmacy, V	ol. 3 (1984) pp	.273-280.		
	FO									inhance Morphine's Analge Pain 82 (1999)pp.1-11.	esic Potency a	nd Attenuate Opioid	Tolerance/depe	endence
	FP	Crain liability	et al., "A	Intagor	nists of uroscie	Excitato	ory Opio	id Rece	eptor Functions E	Inhance Morphine's Analge Pain 84 (2000) pp.121-13	esic Potency ar	nd Attenuate Opioid	Tolerance/depe	endence
	FQ	Fink e	t al., *na	loxone	in Her	oin Dep	endenc	e"; Clin	Pharm and Ther	a. Vol 9, No. 5;pp.568-577				
	FR									ic Dependent Men"; J. Pha		. Thera (1973)Vol 1	0 No. 2;pp.575-	580.
EXAMINER										DATE CONSIDERED				
*EXAMINER: Init						ot citation	on is in	conform	nance with MPEF	9 609; Draw line through cit	tation if not in o	onformance and no	t considered. In	nclude

FORM PTO-1449 (REV. 7-80)									COMMERCE MARK OFFICE	ATTY. DOCKET NO.: 200.1102CON3		SERIAL NO.: 10/694,559		
	LIST	OF P	RIOR	ART	CITED	BY A	PPLIC	CANT		APPLICANT(S): Robert F. KAIKO et al				
	(Use s	several s	sheets i	if neces	ssary)					FILING DATE: October 27, 2003		GROUP: 1615		
								U.	S. PATENT DO	CUMENTS				
*EXAMINER INITIAL		DOC	UMEN	T NUM	BER		-		DATE	NAME	CLASS	SUBCLASS	FILING DATE	
	GA	4	8	6	1	7	6	1	8/89	Goldberg	514	282		
	GB	4	8	6	7	9	8	5	09/19/1989	Heafield et al.	424	461		
	GC	4	8	7	3	0	7	6	10/89	Fishman et al.	412	10		
	GD	4	8	8	2	3	3	5	11/89	Sinclair	514	282		
	GE	4	8	8	9	8	6	0	12/89	Rzeszotarski et al.	514	282		
	GF	4	9	3	5	4	2	θ	8/89	Lewis	514	282		
	GG	4	9	4	0	5	8	7	07/10/1990	Jenkins et al.	424	480		
		_						FOR	EIGN PATENT D	OCUMENTS			_	
		DOC	UMEN	T NUM	BER				DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATIO	ON
													YES	МО
	GH	00	1	9	8	4	7	7	8/16/01	wo	A61P		abstract	
					0	THER F	RIOR A	ART (In	cluding Author, T	itle, Date, Pertinent Page	es, Etc.)			
	GI	Fras 386.	er, Albe	ert D., e	t al., "C	linical T	oxicolo	gy of D	ugs Used in the	Treatment of Opiate Dep	endency"; Clinic	al Toxicology I (199	0) Vol 10, No. 2;	; pp.375-
	GJ	Frey	e et al.,	, "Effect	s of Tra	madol	and Tilio	dine/Na	loxone on Oral-C	aecal Transit & Pupillary	light Reflex'; Arz	zneim-Forsch/Drug	Res. 50(I)(2000)	pp. 24-30.
	GA	Fuda	ala, et a	I., "Effe	cts of B	upreno	rphine a	asnd Na	loxone in Morph	ine-Stabilized Opioid Add	icts"; Drug and A	Alcohol Dependence	e 50 (1998) pp. 1	1-8.
	GJ	Fuda	ala et al	., "Hun	an Pha	rmacolo	ogy and	Abuse	Potential Of Nali	mefene"; Clin Pharm and	Thera (1991) Vo	ol 49, 3, pp. 300-306		
	GM	Gale	et al., "F	Prolong	ed Bloc	kade of	Opioid	Effect v	vith Oral Nalmefe	ene"; Clin Pharm and The	era (1986) pp. 53	7-542.		
	GN	Gerr 41.	a et al.	., "Cloni	idine an	d Opiat	e Rece _l	ptor Ant	agonists in the T	reatment of Heroin Addic	tion"; J. Substar	ice Abuse Treatmer	nt (1995) Vol 12,	1, pp. 35-
	GO	Gho	dse, et	al., "Op	ioid ana	algesics	and Na	arcotic A	Antagonists"; Sid	e Effects of Drugs (2000)	Annual 23, chpt	8 pp. 96-113.		•
EXAMINER	3									DATE CONSIDERED				
*EXAMINER: Initi						ot citation	on is in o	conform	nance with MPEF	1 609; Draw line through o	citation if not in c	onformance and no	t considered. In	clude

FORM PTO-14 (REV. 7-80)	49								COMMERCE ARK OFFICE	ATTY. DOCKET N 200.1102CON3	IO.:	SERIAL NO.: 10/694,559		
	LIST C	F PRI	OR A	RT C	ITED I	BY AF	PLIC	ANT		APPLICANT(S): Robert F. KAIKO e	t al.			
•	(Us	se seve	ral she	ets if n	ecessa	ry)				FILING DATE: October 27, 2003		GROUP: 1615		
								U.S.	PATENT DOC	UMENTS				
*EXAMINER INITIAL		DO	CUME	NT N	ЈМВЕ	R			DATE	NAME	CLASS	SUBCLASS	FILING DA IF APPROP	
	НА	4	2	0	б	0_	9	8	04/29/1980	Ayer, et al.	128	260		
	НЭ	4	9	7	0	ď	7_	5	11/13/1990	Oshlak	424	451		
	НС	4	9	8	7	1	3	6	01/22/1991	Kreek et al.	514	282		
	HD	4	9	0	3	3	2	1	02/05/1991	Goldie et al.	424	484		
	HE	5	0	7	1	6	4	6	12/10/1991	Malkowska et al.	424	497		
	HF	5	0	7	5	3	4	1	12/91	Mendelson et al.	514	282		
	HG	5	0	8	6	0	5	8	2/92	Sinclair et al.	514	282		
							F	OREI	GN PATENT D	OCUMENTS		· · · · · · · · · · · · · · · · · · ·		
		DOG	CUME	NT N	JMBE	R			DATE	COUNTRY	CLASS	SUBCLASS	TRANSLA	ΓΙΟΝ
													YES	NO
	НН	00	1	8	5	1	5	0	11/15/01	wo	A61K	31/00		
	_				ОТНЕ	R PRIC	OR AR	T (Incl	uding Author,	Γitle, Date, Pertinent P	ages, Etc.)			
	ні				1.D. FA 193-1		A New	Metho	od for Detoxifyi	ng Opoiod-Dependent	Patients"; J.	Substance Abuse	Treatment (19	99)
	HJ	Gold	i, et al	. "Rap	id Opic	oid De	toxific	ation D	uring General A	Anesthesia"; Anesthesi	ology (1999)	Vol 91, No 6, pp.	1639-1647.	****
	нк				, "Con No 3, p				narmacology of	Short-Acting μυ Opio	ids in Drug A	busers"; J. Pharm	and Exper Th	era
	HL	Gup	ta, et a	al., "M	orphin	e Com	bined v	with De	oxapram or Nale	oxone"; Anesthesia (19	974) Vol 29, p	р. 33-39.		
	НМ				linical 985)pp				Development of	of Dependence during	Oral Therapy	with Tramadol";	Arzniem-Forso	ch/Drug
	HN		en et a		e effec	t of La	motrig	ine on	Naloxone-preci	pitated Opiate withdra	wal"; Drug ar	nd Alcohol Deper	dence (1998)	Vol 52,
	НО			l., "A l 51-257		udy of	Dextr	ometho	orphan in Nalox	one-Precipitated Opia	te Withdrawal	"; European J. of	Pharm. (1996) Vol
EXAMINER						,				DATE CONSIDER	ED		•	
*EXAMINER: considered. Inc										e with MPEP 609; Dr	aw line throug	h citation if not i	n conformance	e and not

FORM PTO-14 (REV. 7-80)	49								COMMERCE ARK OFFICE	ATTY. DOCKET 1 200.1102CON3	NO.:	SERIAL NO.: 10/694,559		
	LIST	OF PRI	OR A	RT C	ITED :	BY AF	PLIC	ANT		APPLICANT(S): Robert F. KAIKO 6	et al.			
	(U	se seve	ral she	ets if n	ecessa	ry)				FILING DATE: October 27, 2003		GROUP: 1615		
								U.S.	PATENT DOC	UMENTS				
*EXAMINER INITIAL		DOG	CUME	NT N	UMBE	R			DATE	NAME	CLASS	SUBCLASS	FILING DA	
	IA	5	0	9	1_	1_	8	9	02/25/1992	Heafield et al.	424	457		
	IB	5	0	9	6	7	1	5	3/92	Sinclair	424	449		
	IC	5	1	0	2	8	8	7	4/92	Goldberg	514	282		
	ID	4	1	6	0	0	2	0	07/03/1979	Ayer, et al.	424	15		
	IE	5	1	4	9	5	3	8	9/92	Granger et al.	424	449		
	IF	5	2	1	5	7	5	8	06/01/1993	Krishnamurthy	424	488		
IG 5 2 2 5 4 4 0 7/93										London et al.	514	535		
							F	OREI	GN PATENT D	OCUMENTS	_			
		DOC	CUME	NT N	UMBE	R			DATE	COUNTRY	CLASS	SUBCLASS	TRANSLA'	TION
													YES	NO
	IH	00	0	6	7	7	3	9	11/16/00	wo	A61K	31/00		
					OTHE	R PRIC	R AR	T (Incl	uding Author,	Fitle, Date, Pertinent F	Pages, Etc.)			
	נו				prenor 96) Vol					ects during Ascending	Morphine Ma	aintenance in Hur	nans"; J. Phar	m and
	IK								on of Opioid Bl 62-174.	ockade Produced by I	Buprenorphine	and Naltrexone i	n Humans";	
	IL				lonspec					: Reverse-Order Preci	pitated Withd	rawal and Dose-I	Oose Interactio	ns':
	IM								/al-like Sympton 20, 4, pp. 445-	ns by Cocaine Abuse 458.	during Metha	done and Bupren	orphine Maint	enance";
	IN	Stine	e et al.	, "Use	of Dru	g Com	binatio	ons in	Treatment of Op	piopd Withdrawal"; J.	Clinical Psyc	h. (1992) Vol 12,	No 3, pp. 203	-209.
	Ю	Stoll	ler et a	1. , " Efi	fects of	bupre	norphi	ne/nale	oxone in opioid	-dependent humans" I	sychopharma	cology (2001) Vo	ol 154, pp. 230	-242.
	IP			-	ute Eff					one and naloxone in r	nethadone-ma	intained voluntee	ers"; J. Pharm	and
	IQ	Stra	in et al	., "Eff		bupre				ne/naloxone tablets in	non-depender	nt opioid abusers'	'; Psychopharn	nacology
-	IR	Stra	in et al	., "Рге		ed Wit	hdrawa	al by P	entazocine in M	ethadone-Maintained	Volunteers";	J. Pharm and Exp	per Thera (199	3) Vol
	IS						tagoni	st The	rapy for Heroin	Addiction"; NIDA (19	997) 5 nages			
EXAMINER	1.5	1		1 14111	<u> </u>					DATE CONSIDER				
*FX 4 1 4 10 10 10 10 10 10 10 10 10 10 10 10 10				•••				-	i	- 141 MARTER COO. 5	•• ••		-	
*EXAMINER: considered. Inc	initial if lude cop	reference y of thi	ce con: s form	sidered with r	ı, whet next co	ner or mmun	not cita	ation is to app	in contormanc licant.	e with MPEP 609; Dr	aw line throug	n citation if not i	n conformance	e and not

FORM PTO-144 (REV. 7-80)	49								COMMERCE ARK OFFICE	ATTY. DOCKET N 200.1102CON3	1O.:	SERIAL NO.: 10/694,559		
	LIST (OF PR	IOR A	RT C	ITED I	BY AF	PLIC	ANT		APPLICANT(S): Robert F. KAIKO e	t al.			
	(U	se seve	ral she	ets if n	ecessa	ry)				FILING DATE: October 27, 2003		GROUP: 1615		
								U.S.	PATENT DOC	UMENTS				
*EXAMINER INITIAL		DO	CUME	ENT N	JMBE	R			DATE	NAME	CLASS	SUBCLASS	FILING DA IF APPROP	
	JA	5	2	2	6	3	3	1	07/13/1993	Thompson et al.	73	865.9		
	JB	5	2	3	6	7	1	4	8/93	Lee et al.	424	449		
	JC	5	2	5	6	6	6	9	10/93	Askanazi et al.	514	282		
	JD	5	2	6	6	3	3	1	11/30/1993	Oshlak et al.	424	468		
	JE	5	2	7	3	7	6	0	12/93	Oshlak et al.	424	486		
	JF	5	2	8	6	4	9	3	02/15/1994	Oshlak et al.	424	468		
	JG	5	3	1	6	7	5	9	12/93	Rose et al.	424	10		
							F	OREI	GN PATENT D	OCUMENTS				
		DO	CUME	ENT N	UMBE	:R			DATE	COUNTRY	CLASS	SUBCLASS	TRANSLA	TION
													YES	NO
	JH	00	0	5	1	5	9	2	9/05/00	wo	A61K	31/14		
				,	отне	R PRIC	OR AR	T (Inc	luding Author,	Γitle, Date, Pertinent F	Pages, Etc.)			
	JI		bricht -190	et al., '	'Naltre	xone s	horten	ed opic	oid detoxificatio	n with buprenorphine	"; Drug and A	decohol Dependen	ce (1999) Vol	56 pp.
	JK	Vac	carino	et al.,	"Enog	enous	Opiate	s: 1999	o"; Peptides 21 (2000) pp. 1975-2034				
	JL	Wai	ng et a	ıl., "Inv	erse A	gonists	and n	eutral a		opioid receptor (MOI		le of basal recept	or signaling in	narcotic
	JM									ependence"; Annals N	ew York Aca	demy of Sciences,	pp. 252-261.	
	JN	1		-						analgesics"; Clin Phar				
	10	We Lin	lls, et a	al., "In intinoc	vivo P	harmad	cologic	al Cha	racterization of	SoRI 9409, a Nonpep one Physical Depende	tidic Opioid p	-Agonist/δ-Antag	gonist that Pro	duces 97, No 2,
	JP				rug Tr	eatme	nt for C	Opioid	Dependence"; A	Australian Prescriber (2001) Vol 24.	No 1, pp. 4-6.		
	1Q	Wri	ight et	al., "A	cute pl	nysical	depen	dence i		ated naloxone-precipi			dose of metha	done";
	JR	Zhu	ı et al.,	, "Naltr	exone-	precip	itated	morphi	ne withdrawal i	n infant rat is attenuat Vol 150, pp. 325-33		dministration if N	OS inhibitors	but not
EXAMINER										DATE CONSIDER				
*EXAMINER: considered. Inc										e with MPEP 609; Dr	aw line throu	gh citation if not i	n conformance	e and not

FORM PTO-144 (REV. 7-80)	19								COMMERCE ARK OFFICE	ATTY. DOCKET N 200.1102CON3	O.:	SERIAL NO.: 10/694,559		
	LIST C)F PRI	OR A	RT CI	TED I	ву ар	PLIC	ANT		APPLICANT(S): Robert F. KAIKO et	: al.			_
	(Us	se sever	al she	ets if n	ecessa	ry)				FILING DATE: October 27, 2003		GROUP: 1615		
								U.S.	PATENT DOC	UMENTS				
*EXAMINER INITIAL		DOC	CUME	NT NI	JMBE	R			DATE	NAME	CLASS	SUBCLASS	FILING DA IF APPROP	
	KA	5	3	1	7	9	2	2	5/94	Borsodi et al.	514	282		
	KB	5	3	2_	1	0	1	2	6/94	Mayer et al.	514	25		
	KC	5	3	2	4	3	5	1	06/28/1994	Oshlak et al.	106	153		
	KD	5	3	3_	6	6	9	1	08/09/1994	Raffa et al.	514	629		
	KF	5	3	5	2	6	8	0_	10/94	Portoghese et al.	514	279		
	KF	5	3	5	2	6	8	3	10/94	Mayer et al.	514	289		
	KG	.5	3	5	6	4	6	7	10/18/1994	Oshlak et al.	106	153	ļ	
							F	OREI	GN PATENT D	OCUMENTS				
		DOG	CUME	NT N	имве	R			DATE	COUNTRY	CLASS	SUBCLASS	TRANSLA	TION
													YES	NO
	КН	8	1	5	8	4	5	1	08/19/2001	WO (A1)	A61K	31/485		
					ОТНЕ	R PRIC	OR AR	T (Inc	uding Author,	Γitle, Date, Pertinent P	ages, Etc.)			
	KI									ine prodrug controlled narm (1999) Vol 177,		ect of formulation	variable on dr	rug
	КJ	Han	dal et	al., "N	aloxon	e"; An	nals of	Emer	gency Medicine	(1983) Vol 12:7, pp. 4	138-445.			
	кк								co-administrati 61, pp. 85-94.	on in opiate dependen	t patients stal	oilized on subling	ual buprenorpi	hine";
	KL				iffect o			ase for	mulation of nalo	oxone on intestinal trai	nsit in volunte	ers taking codein	e"; Aliment Pl	harm
	КМ	Hög	ger et	al., "C	ompari	ison of	tilidin	e/nalo:	cone, tramadol a	and bromfenac in expe	rimental pain) Vol 37, No	: a double-blind r 8,pp. 377-385	andomized cro	ssover
	KN	1	4							re's Clinical Anesthes			993-1011.	
	ко	Crai	n et al	., "Ultı	ra-low	concer	tration	ns of na	aloxone selectiv	ely antagonize excitate ance/dependence				hereby
	KP									tic Agonist/Antagonis	Analgesic";	NIDA Research (1979) pp. 99-1	105.
	ко	Leel	ing et		isposit					in the rat, dog, and ma				
EXAMINER	•	1	, , , ,							DATE CONSIDER	ED			
*EXAMINER: considered. Inc										e with MPEP 609; Dr	aw line throug	gh citation if not i	n conformance	e and not

FORM PTO-14 (REV. 7-80)	49								COMMERCE ARK OFFICE	ATTY. DOCKET N 200.1102CON3	0.:	SERIAL NO.: 10/694,559		
	LIST (OF PR	IOR A	RT CI	TED 1	ву ар	PLIC	ANT		APPLICANT(S): Robert F. KAIKO et	al.			
	(U	se seve	ral she	ets if n	ecessa	ry)				FILING DATE: October 27, 2003		GROUP: 1615		
								U.S.	PATENT DOC	UMENTS				
*EXAMINER INITIAL		DO	CUME	NT NU	JMBE	R			DATE	NAME	CLASS	SUBCLASS	FILING DA IF APPROP	_
	LA	5	3	5	6	9	0	8	10/94	Bihari et al.	514	282		
	LB	5	3	7	6	6	6	2_	12/94	Ockert	514	282		
	LC	3	5	4	1	0	0	5	11/17/1970	Strathmann, et al.	210	19		
	LD	5	4	1	1	7	4	5	05/02/1995	Oshlack et al.	424	456		,
	LE	5	4	7	6	1	1	2	06/95	Zagon et al.	514	282		
	LF	3	5	4	1	0	0	6	11/17/1970	Bixler, et al.	210	23		
,	LG	5	4	5	7	2	0	8	10/95	Portoghese et al.	546	35	,	
							F	OREI	GN PATENT D	OCUMENTS				
		DOC	CUME	NT NU	JMBE	R			DATE	COUNTRY	CLASS	SUBCLASS	TRANSLAT	TION
										:			YES	NO
	LH	0	8	8	0	3	5	7	02/03/1998	EP (B1)	A61K	31/485		х
				(ЭТНЕ	R PRIC	R AR	T (Incl	uding Author, T	litle, Date, Pertinent P	ages, Etc.)	-		
	LI					of daily				gimens with the comb	bation bupre	norphine-naloxon	e tablet"; Drug	g and
	u									and naltrexone in rats'	';(1987) Vol	36, pp. 127-130.		
	LP	Jasii	nski et		he hun	nan ph				tial of N-allylnoroxyme			nd Exper Ther	a (1967)
	LM	Jone	es et al.	., "Nalı	mefene				enous morphine	challenge effects in op	oioid abusinh	humans"; Drug a	nd Alcohol	
	LN								oxone-Precinita	ted Withdrawal in Hur	nan Onioid-F	Penendent Subject	s"· I Pharma a	und
						1 260,							, , , , , , , , , , , , , , , , , ,	
	ю					Biotra				f Subjective Side Effe	cts: A Prelimi	nary Study"; Alco	oholism: Clin a	and
	LP	Kog	an et a	l., "Est ral Adr	timatio ninistr	n of th	e Syste	emic A	vailability and (In Chem. Path.	Other Pharmacokinetic And Pharm (1977) V	Parameters of 18, No. 1,	of Naltrexone in N	Man after Acut	e and
	LQ									oine-Abusing Heroin A			/ (1994) Vol 1,	, p 151.
	LR		ten et a							ne maintained patients				
	LS	Kur	land et	al., "N 663-67		ne and	the Na	rcotic	Abuser: A Cont	rolled Study of Partial	Blockade"; I	nter. J. of the Add	lictions (1974)	Vol 9,
EXAMINER		1 2.0	-, _P P· (. 55 01.						DATE CONSIDER	ED			
*EXAMINER:										e with MPEP 609; Dra	w line throug	gh citation if not i	n conformance	and not

FORM PTO-14 (REV. 7-80)	49								COMMERCE ARK OFFICE	ATTY. DOCKET 1 200.1102CON3	NO.:	SERIAL NO.: 10/694,559		
	LIST (OF PR	IOR A	RT C	ITED :	BY AF	PLIC	ANT		APPLICANT(S): Robert F. KAIKO	et al.			
	(U	se seve	ral she	ets if n	ecessa	гу)				FILING DATE: October 27, 2003		GROUP: 1615		
								U.S.	PATENT DOC	UMENTS				
*EXAMINER INITIAL		DO	CUME	ENT N	JMBE	R			DATE	NAME	CLASS	SUBCLASS	FILING DA	
	MA	5	4	6	9	8	2	6	10/24/1995	Merrill et al.	424	470		
	МВ	5	4	7	2	7	1	2	12/05/1995	Oshlack et al.	424	480		
	мс	5	4	7	2	9	4	3	12/95	Crain et al.	514	12		
	MD	5	4	7	0	5	7	7	12/26/1995	Sackler et al.	424	480		
	ме	5	4	8	6	3	6	2	1/96	Kitchell et al.	424	426		
	MF	5	5	0	0	2	2	7	03/19/1996	Oshlack et al.	424	476		
	4	-4	4,				F	OREI	GN PATENT D	OCUMENTS	•			
		DO	CUME	ENT N	UMBE	R			DATE	COUNTRY	CLASS	SUBCLASS	TRANSLA	TION
													YES	NO
	MG													
	•				OTHE	R PRIC	OR AR	T (Inc	luding Author,	Fitle, Date, Pertinent	Pages, Etc.)		•	
	МН	Lee 815							V 1	vents Tolerance and l		Anesth Analg (19	97) Vol 84, pp	o.810-
	МІ			t al.,"Is			aloxon	e on th	ne Postoperative	Analgesic and Respi	ratory effects	of Buprenorphine	"; Eur. J. Clin	Pharm
	МЈ	T					Pentaz	ocine /	Analgesia by Lo	w-dose Naloxone"; J	Clin Invest (1	988) Vol 82, pp. 1	1574-1577.	
	мк	Loii	mer et		ombine	ed Nalo				ns for Opiate Substitu				ent
	ML	Mar	rtin et a	al. "Bio	oavaila	bility I	200	100	of a New Tilidir pp. 599-607.	ne/Naloxone Liquid F	ormulation Co	mpared to a Refe	rence Formula	tion";
	ММ	Mar	rtin et :		emonst	ration	of Tole	erance		Dependence on N-all	ynormorphine	(Nalorphine)";J.	Of Pharm and	Exper
	MN	Mei	ndelso	n et al.,	"Bupi	enorph	nine an	d nalo	xone combination	ons: the effects of thre	ee dose ratios i	n morphine stabi	lized, opiate-d	ependent
	мо	Mei	ndelso		"Bupi	enoph	ine and			s in Methadone Main	tenance Patien	ts"; Society of Bi	ological Psych	iatry
	МР	1	t et al.					xture f	or use in metha	done maintenance pro	ograms"; Clin	Pharm and Ther.	Vol 15, No 2.,	pp 156-
EXAMINER		1 100								DATE CONSIDER	RED			
*EXAMINER:										e with MPEP 609; Di	raw line throug	gh citation if not i	n conformanc	e and not

FORM PTO-14 (REV. 7-80)	49								COMMERCE ARK OFFICE	ATTY. DOCKET N 200.1102CON3	4O.:	SERIAL NO.: 10/694,559		
	LIST C)F PR	IOR A	RT C	ITED I	ВҮ АР	PLIC	ANT		APPLICANT(S): Robert F. KAIKO e	t al.			
	(Us	se seve	ral she	ets if n	ecessa	ry)				FILING DATE: October 27, 2003		GROUP: 1615		
								U.S.	PATENT DOC	UMENTS				
*EXAMINER INITIAL		DO	CUME	ENT NI	UMBE	R			DATE	NAME	CLASS	SUBCLASS	FILING DA IF APPROP	
	NA	5	5	8	2	0	5	0	3/96	Mayer et al.	514	289		
	NB	5	5	0	8	0	4	2	04/16/1996	Oshlack et al.	424	468		
	NC	5	5	0	8	0	4	3	04/16/1996	Krishnamurthy	424	484		
	ND	5	5	1	2	5	7	8	4/96	Crain et al.	514	282		,
	NE	5	5	1	4		8	0	5/96	Weber et al.	514	249		
							F	OREI	GN PATENT D	OCUMENTS				
		DO	CUME	ENT N	ЈМВЕ	R			DATE	COUNTRY	CLASS	SUBCLASS	TRANSLAT	rion
													YES	NO
	NE													
					OTHE	R PRIC	R AR	T (Incl	uding Author, 1	Title, Date, Pertinent F	ages, Etc.)			
	NG		vatikaı 941-94	r et al.,						the Treatment of Her		Clin. Pharm and	Thera, Vol 14,	No. 6,
	NH		vartika 0-1354		, "Nalo	xone-l	Methac	ione C	ombination for	the Treatment of Opia	te Dependenc	e"; Missouri Insti	tute of Psychia	itry, pp.
	NI	Alo		in Cor						ffects of Kappa Opioi irrel Monkeys"; J of P				
	NK			al., "B		rphine	and N	aloxon	e alone and in o	ombination in Opioid	-dependant H	umans"; Psychop	harmacology (1988),
	NK			al., "D ra (199						romorphone and Penta	azocine Effect	s in Human Volu	nteers"; J of Ph	narm and
	NL			al., "E o. 27-34		of Subl	inguall	y give	n naloxone in O	pioid -dependant hum	nan volunteers	'; Drug and Alco	hol Dependenc	ce (1990)
	NM								ment of Bupren hool of Medicir	orphine-Naloxone Co.	mbinations"; I	Dept of Psychiatry	y and Behavior	ral
	NN									and Precipitation of A				on to
EXAMINER										DATE CONSIDER	ED			
										Le with MPEP 609; Dr	aw line throug	h citation if not i	n conformance	and not
considered. Inc	lude cop	y of th	is form	with r	next co	mmun	ication	to app	licant.					

١

FORM PTO-14 (REV. 7-80)	49								COMMERCE ARK OFFICE	ATTY. DOCKET 200.1102CON3	NO.:	SERIAL NO.: 10/694,559		
	LIST						PPLIC	ANT		APPLICANT(S): Robert F. KAIKO	et al.			
	(Us	se seve	ral she	ets if n	ecessa	ry)				FILING DATE: October 27, 2003		GROUP: 1615		_
								U.S.	PATENT DOC	UMENTS				
*EXAMINER INITIAL		DO	CUME	ENT N	JMBE	R			DATE	NAME	CLASS	SUBCLASS	FILING DA	
	OA	5	5	3	4	4	9	2	7/96	Aston et al.	514	608		
<u> </u>	ОВ	5	5	4	9	9	1	2	08/27/1996	Oshlack et al.	424	468	-	
	ос	5	5_	5	2	4	2	2	09/03/1996	Gauthier et al.	514	368		
	OD	5	5	5	6	8	3	8	9/96	Mayer et al.	514	25		
	OE	5	5	7_	4	0	5	2	11/96	Rose et al.	514	343		,
							_ F	OREI	GN PATENT D	OCUMENTS			1	
		DOG	CUME	ENT N	UMBE	R			DATE	COUNTRY	CLASS	SUBCLASS	TRANSLA	TION
													YES	NO
	OF													
					OTHE	R PRIC	OR AR	T (Inc	luding Author,	Γitle, Date, Pertinent	Pages, Etc.)			
	OG	Zak	s et al.	, "Nalo	xone	Γreatm	ent of	Opiate	Dependence";	JAMA (1971) Vol 21	15, No 13, pp. 2	2108-2110.		
	ОН	Bart	ton, et	al., "In	tranas	al Adn	ninistra	tion of	f Naloxone by P	aramdeics";Prehospi	tal Emergency	Care (2002) Vol	6, No 1, pp. 54	1-58.
	OI	Blac	hly, P	aul, H.	, M.D.	, "Nalo	oxone i	n Opia	ate Addiction";	Current Psychiatric	Therapies (1976) pp. 209-213.		
	Oì			t al., "R (1995)					controlled-releas	e oral morphine sulf	ate during naltr	exone blockade";	Inter J of Clin	Pharm
	ок	Jasii 258.		D.R., "/	Assessi	ment o	f the A	buse P	oteniality of Mo	orphinelike Drugs (M	lethods Used in	Man)"; Drug Ad	diction (1977) pp. 197-
	OL	Johr	ison e	t al., "E	Bupren	orphin	e and N	Valoxo	ne for Heroin D	ependence"; Substar	nce Use Disorde	ers (2000) pp. 519)-526.	
	ОМ	Stra 217		ıl., "Op	ioid an	itagoni	st effec	ets of d	lezocine in opio	id-dependent human	s"; Clin Pharm	and Thera (1996)	Vol 60, No 2	, pp. 206-
	ON	Pres 49-8		al., "A	buse li	ability	and st	udies o	of opioid agonis	t-antagonists in hum	ans"; Drug and	Alcohol Depende	ence (1991) vo	ol 28, pp.
	00									Valoxone after Admi sch/Drug Res. (2000			olution or	
EXAMINER										DATE CONSIDE	RED			
*EXAMINER: considered. Inc										e with MPEP 609; D	Oraw line throug	gh citation if not i	n conformanc	e and not

FORM PTO-14 (REV. 7-80)	49								COMMERCE ARK OFFICE	ATTY. DOCKET 1 200.1102CON3	NO.:	SERIAL NO.: 10/694,559		
	LIST (OF PR	OR A	RT C	TED	BY AF	PLIC	ANT		APPLICANT(S): Robert F. KAIKO e	et al.			
	(U	se seve	ral she	ets if n	ecessa	ry)				FILING DATE: October 27, 2003		GROUP: 1615		
			-					U.S.	PATENT DOC	UMENTS				
*EXAMINER INITIAL		DO	CUME	NT N	JMBE	R			DATE	NAME	CLASS	SUBCLASS	FILING DA IF APPROF	
	PA	5	5	7	8	7	2	5	11/96	Portoghese et al.	546	35		
	PB	5	5	8	0	8	7	6	12/96	Crain et al.	514	282		www.
	PC	5	5	8	5	3_	4	8_	12/96	Crain et al.	514	12		
	PD	5	5	9	1	4	5	2	01/04/1997	Miller et al.	424	468		
	PE	5	6	0	1	8	4	5_	02/11/1997	Buxton et al.	424	495	! 	
							F	OREI	GN PATENT D	OCUMENTS				
		DOG	CUME	NT N	ЈМВЕ	R			DATE	COUNTRY	CLASS	SUBCLASS	TRANSLA	TION
													YES	NO
	PF				-									
					OTHE	R PRIC	OR AR	T (Inc	luding Author,	litle, Date, Pertinent I	Pages, Etc.)			
	PG	Ben	fey, "F	unctio	n of M	yocard	lial α-A	Adrenc	ceptors"; Life S	Sciences (1982) vol 3	1, pp. 101-112	•		
	PH	Lev	ine et a	ıl., "Po	tentiat	ion of	Pentaz	ocine 1	Analgesia by Lo	w-dose Naloxone"; J	of Clin Invest.	(1988) Vol 82, p	p. 1547-1577.	
	PI			al., "O 994), '					Receptor Upreg	ulation: Effects of Co	ncurrent Agor	ist Administratio	n"; Brain Res	earch
	РJ								sue Distribution rs (1994) pp. 28	of a Putative Member 34-288.	r of the Rat Op	pioid Receptor Ge	ne Family tha	t is not a
	PK			et al.,), pp. 3		l, a no	velmei	mber o	f the opioid rece	eptor family: Cloning,	functional ex	pression and loca	lization"; FEB	S letters
	PL		ng, et a			oning a	=of an	orpha	n opiate recepto	or gene family membe	r and its splice	variant"; FEBS	letters 348 (19	94) pp.
	PM	Suz	uki et a						preference after	chronic treatment wi	th naloxone in	the rat"; Researc	h Communica	itions in
EXAMINER	•									DATE CONSIDER	RED			
*EXAMINER: considered. Inc										e with MPEP 609; Dr	raw line throug	sh citation if not i	n conformance	e and not

FORM PTO-14 (REV. 7-80)	49								COMMERCE ARK OFFICE	ATTY. DOCKET N 200.1102CON3	VO.:	SERIAL NO.: 10/694,559		
	LIST C						PLIC	ANT		APPLICANT(S): Robert F. KAIKO e	t al.			
	(Us	se seve	ral she	ets if n	ecessa	ry)				FILING DATE: October 27, 2003		GROUP: 1615		
		_						U.S.	PATENT DOC	UMENTS				
*EXAMINER INITIAL		DO	CUME	NT N	ЈМВЕ	R			DATE	NAME	CLASS	SUBCLASS	FILING DA IF APPROP	
	QA	5	6	1	6	6_	0	1	4/97	Khanna et al.	514	399		
	QB	5	6	2	2	7	2	2	04/22/1997	Knott et al.	424	494		
	QC	5	6	2	4	9	3	2	4/97	Qin et al.	514	282		
	QD	5	6	3	3	2_	5	9	5/97	Qin et al.	514	282		
	QF	5	6_	3	9	4	7	6	06/17/1997	Oshlack et al.	424	468		
							F	OREI	GN PATENT D	OCUMENTS			_	
		DO	CUME	ENT N	JMBE	R			DATE	COUNTRY	CLASS	SUBCLASS	†RANSLA	ΓΙΟΝ
													YES	NO
	OF													
	1				OTHE:	R PRIC	OR AR	T (Incl	uding Author, 1	Γitle, Date, Pertinent F	ages, Etc.)			
	QG				ternati	onal P				shed on Abuse-Resist		ever Being Develo	ped by Perdue	
	QН			al., "In 9 (2), p			gesic F	otency	of Mu Agonist	s after Continuous Na	loxone Infusi	on in Rats"; J fo I	Pharm Exper T	hera
	QI								nalgesics Follo Vol 51 No. 2, j	wing Chronic Opioid op. 535-539.	Antagonist Ti	reatment: Relation	ship to Recep	tor
	ΟΊ									se morphine in norma) Vol 888, pp. 75-82.	al mice is bloc	ked by ultra-low-	dose naltrexon	e,
	QK								d Receptors in I Vol 82., pp. 22	Rat and Monkey Dors. 3-240.	al Root Gangl	ion Neurons and	Spinal Cord A	fter
	QL	Abd	lulla et		xotom	y redu	ces the	effect	of analgesic op	ioids yet increases the	effect of noc	iceptin on dorsal	oot ganglion n	eurons";
	QM	Di 0	Giannu		al., "C	rphani	in FQ r	educes	morphine-indu	ced dopamine release	in the nucleu	s accumbens: a m	icrodialysis stu	udy in
EXAMINER										DATE CONSIDER	ED			
*EXAMINER: considered. Inc										e with MPEP 609; Dr	aw line throu	gh citation if not i	n conformance	e and not

FORM PTO-14- (REV. 7-80)	49								COMMERCE ARK OFFICE	ATTY. DOCKET N 200.1102CON3	O.:	SERIAL NO.: 10/694,559		
	LIST C	F PRI	OR A	RT CI	TED I	BY AP	PLIC	ANT		APPLICANT(S): Robert F. KAIKO et	al.			
	(Us	e seve	ral she	ets if n	ecessai	ry)				FILING DATE: October 27, 2003		GROUP: 1615		
								U.S.	PATENT DOC	UMENTS				
*EXAMINER INITIAL		DOG	CUME	אד אנ	JMBE	R			DATE	NAME	CLASS	SUBCLASS	FILING DA IF APPROP	
	RA	5	6	5	6	2	9	5	08/12/1997	Oshalck et al.	424	490		
	RB	5	6_	7	ď	1	7	2	09/23/1997	Buxton et al.	424	495		
	RG	5	6	7	2	3	8	S	09/30/1997	Sackler et al.	424	490		
	RD	5	6	8	1	5	8	5	10/28/1997	Oshlack et al.	424	494		
	RE	5	7	6	3	4	5	2	06/09/1998	Miller et al.	514	282		
	RF	5	7	6	7	1	2	5	06/98	Crain et al.	514	282		
	RG	5	7	8	0	4	7	9	07/14/1998	Kim	514	282		
	RH	5	7	6	7	1	2	5	06/16/1988	Crain, et al.	514	282		
	RI	6	0	9	6	7	5	6	08/01/2000	Crain, et al.	514	282		
	RJ	6	1	9	4	3	8	2	02/27/01	Crain, et al.	514	2		
	RK	6	3	6	2	1	9	4	03/26/2002	Crain, et al.	514	285		
	RL	6	3	9	5	7	0	5	05/28/2002	Crain, et al.	514	2		
	RM	20	01	00	06	9	6	7	07/05/2001	Crain, et al.	514	253.04		
	RN	20	01	00	18	4	1	3	08/30/2001	Crain, et al.	514	2		
							F	OREI	GN PATENT D	OCUMENTS				1,
		DOC	CUME	NT NU	JMBE	R			DATE	COUNTRY	CLASS	SUBCLASS	TRANSLAT	rion
													YES	NO
	RO													
					OTHER	R PRIC	R AR	T (Incl	uding Author, T	Title, Date, Pertinent Pa	ages, Etc.)			
	RP		ociopp		., "Effe	ect of l	Nocice	ptin/or	phanin FQ on tl	ne Rewarding Propertie	es of Morphir	e"; Eur. J Pharm	acol (2000) Vo	ગ 404,
	RQ	Phys	sician':	Desk	Refere	ence (2	001) s	ee Rev	ia, pp. 1146-114	49 and Oxycontin, pp.	2697-2701			ĺ
	RR													
	RS			*								<u>-</u>		
EXAMINER										DATE CONSIDERI	ED			
*EXAMINER: I	nitial if r	eferen	ce cons	sidered	, whetl	her or	not cita	ation is	in conformance	L e with MPEP 609; Dra	w line throug	h citation if not in	n conformance	and not

FORM PTO-14- (REV. 7-80)	49								COMMERCE ARK OFFICE	ATTY. DOCKET No	O.:	SERIAL NO.: 10/694,559		
(NEV. /-80)	LIST C	F PR	IOR A						MAK OFFICE	APPLICANT(S): Robert F. KAIKO et	al	10/024,337		
	(Us	se seve	ral she	ets if n	ecessai	ry)				FILING DATE: October 27, 2003	ai.	GROUP: 1615		
-				-				116	PATENT DOC			[1013		-
*EXAMINER	1	DO	CLIME	NT NU	IMDE			0.3.	DATE	NAME	CLASS	SUBCLASS	FILING DA	
INITIAL		ВО	T	INI INI	JIVIDE.				DATE	IVAIVIE	CLASS	SOBCLASS	IF APPROP	
	SA	5	8	1	1	1	2	6	09/22/1998	Krishnamurthy	424	498		
	SB	5	8	3	4	4	7	7	11/10/1998	Mioduszewski	514	282		
	sc	5	8	4	3_	4	8	0	12/01/1998	Miller et al.	424	484		
	SD	5	8	4	9	2	4	0	12/15/1998	Miller et al.	264	460		
	SE	5	8	5	8	0	1	7	1/99	Demopulos et al.	604	890.1		
	SE	5	8	6_	0_	9	5	0	1/99	Demopulos et al.	604	49		
	SG	5	8	6	6	1	6	4	2/99	Kuczynski et al.	424	472		
	SH	5	4	0	9	9	4	4	04/25/1995	Black et al.	514	359		
	SI	5	1	3	8	3	1	1	07/14/1992	Guillaumet et al.	514	234.2		
	SJ	4	4	0	1	6	7	2	08/30/1983	Portoghese	424	260		
	SK	4	4	5	7	9	3	3	07/03/1984	Gordon et al.	424	260		
	SL	5	4	3	6	2	6	5	07/25/1995	Black et al.	514	420		
•	SM	5	6	3	9	7	8	0	06/17/1997	Lau et al.	514	419		
	SN	5	6	0	4	2	6	0	02/18/1997	Guay et al.	514	605	•	
	so	5	6	0	4	2	5	3	02/18/1997	Lau et al.	514	419		
	SP	5	5	9	3	9	9	4	01/14/1997	Batt et al.	514	252		
<u></u>		1									514	602		
	SQ	5	5	3	6	7	5	2	07/16/1996	Ducharme et al.			<u> </u>	
	SR	5	5	5	0	1	4	2	08/27/1996	Ducharme et al.	514	365		
	SS	5	5	2	1	2	1	3	05/28/1996	Prasit et al.	514	460	<u> </u>	··
	ST	5	5	1	0	3	6	8	04/23/1996	Lau et al.	514	419		
	SU	5	4	7	4	9	9	5	12/12/1995	Ducharme et al.	514	241		
· <u>·</u> ····	Ι	Γ					F	OREI	GN PATENT D			<u> </u>		
		DO	CUME	ENT N	UMBE	R			DATE	COUNTRY	CLASS	SUBCLASS	TRANSLA	
													YES	NO
	sx													
					ОТНЕ	R PRIC	OR AR	T (Inc	luding Author,	Fitle, Date, Pertinent Pa	ages, Etc.)			
	SY													
EXAMINER										DATE CONSIDERI	ED			
*EXAMINER:	Initial if	referen	ice con	sidered	i, whet	her or	not cit	ation is	s in conformanc	e with MPEP 609; Dra	w line throug	h citation if not i	n conformance	e and not

FORM PTO-14 (REV. 7-80)	49								COMMERCE ARK OFFICE	ATTY. DOCKET 1 200.1102CON3	NO.:	SERIAL NO.: 10/694,559		
	LIST (OF PR	IOR A	RT C	ITED I	BY AF	PLIC	ANT		APPLICANT(S): Robert F. KAIKO 6	et al			
	(U	se seve	ral she	ets if n	ecessa	гу)				FILING DATE: October 27, 2003		GROUP: 1615		
								U.S.	PATENT DOC	CUMENTS				
*EXAMINER INITIAL		DO	CUME	ENT N	UMBE	R			DATE	NAME	CLASS	SUBCLASS	FILING DA	
	TA	5	8	6	9	0	9	7	02/09/1999	Wong et al.	424	473		
	ТВ	5	8	7	9	7	0	5	03/09/1999	Heafield et al.	424	464		
	TC	5	8	8	0	1	3	2	3/99	Hill	514	282		
	TD	5	8	9	1	4	7	1	04/06/1999	Miller et al.	424	468		
	TE	5	9	0_	8	8	4	8	06/01/1999	Miller et al.	514	282		
	TF	5	9	4	2	2	4	1	8/99	Chasin et al.	424	426		
	TG	5	9	5	8	4	5	2	09/28/1999	Oshlack et al.	424	457		
	TH	3	8	4	5	7	7	0	11/05/1974	Theeuwes et al.	128	260		
	TI	4	0_	6_	3	0	6	4	12/13/1977	Saunders et al.	219	121		
	TJ	4	0	8	8	8	6_	4	05/09/1978	Theeuwes et al.	219	121		
	TK	4	2	9	3	5	3	9	10/06/1981	Ludwig et al.	429	19		
	TL	4	9	5	7	6	8	1	09/18/1990	Klimesch et al.	264	211.23		
							F	OREI	GN PATENT D	OCUMENTS				
		DO	CUME	NT NI	UMBE	R			DATE	COUNTRY	CLASS	SUBCLASS	TRANSLA	TION
													YES	NO
	TM				•									
		-		(отне	R PRIC	OR AR	T (Incl	uding Author, T	litle, Date, Pertinent I	ages, Etc.)			
	TN												•	
	то													
	TP													
	TQ													
	TR													
	TS													
EXAMINER									- 12	DATE CONSIDER	ED			
	TM OTHER PRIOR ART (Including of the transfer									e with MPEP 609; Dr	aw line throug	gh citation if not i	n conformance	e and not

FORM PTO-14- (REV. 7-80)	49								COMMERCE ARK OFFICE	ATTY. DOCKET 200.1102CON3	NO.:	SERIAL NO.: 10/694,559		
	LIST (OF PR	IOR A	RT C	ITED	BY AF	PLIC	ANT		APPLICANT(S): Robert F. KAIKO	et al.			
	(U	se seve	ral she	ets if r	ecessa	ry)				FILING DATE: October 27, 2003		GROUP: 1615		
								U.S.	PATENT DOC	CUMENTS				
*EXAMINER INITIAL		DO	CUME	ENT N	UMBE	R			DATE	NAME	CLASS	SUBCLASS	FILING DA	
	UA	5	9	5	8	4_	5	9_	09/28/1999	Chasin et al.	424	490		
	UB	5	9	6	5	1_	6	1	10/12/1999	Oshlack et al.	424	457		
	UC	5	9	6	5	1	6	3	10/12/1999	Miller et al.	424	468		
	UD	5	9	6	8	5	4	7	10/99	Reder et al.	424	449		
	UE	5	9	6	8	5	5	1	10/19/1999	Oshlack et al.	424	456		
	UF	5	9	7	2	9	5	4	10/99	Foss	514	282		
	UG	5	9	9	8	4	3	4	12/99	Mitch et al.	514	210.16		
	UH	3	1_	7	3	8	7	7	03/16/1965	Jackson et al.	252	138		
							F	OREI	GN PATENT D	OCUMENTS		•	•	
		DO	CUME	ENT N	UMBE	R			DATE	COUNTRY	CLASS	SUBCLASS	TRANSLA	TION
													YES	NO
	UI													
	UJ													
	UK													
	UL													
					ОТНЕ	R PRIC	OR AR	T (Incl	uding Author,	Γitle, Date, Pertinent	Pages, Etc.)			
	UM													
	UN													
	UO													
	UP													
	UQ													
	UR													
	US													
EXAMINER										DATE CONSIDE	RED			
*EXAMINER: considered. Inc										e with MPEP 609; D	raw line throug	gh citation if not i	n conforman	ce and not

FORM PTO-1449 U.S. DEPARTMENT OF COMMER PATENT AND TRADEMARK OFF										ATTY. DOCKET NO.: SERIAL NO.: 10/694,559				
LIST OF PRIOR ART CITED BY APPLICANT									APPLICANT(S): Robert F. KAIKO et al.					
(Use several sheets if necessary)										FILING DATE: GROUP: 0ctober 27, 2003 1615				
	-						Ü	U.S.	PATENT DOC					
*EXAMINER INITIAL		DO	CUME	ENT N	UMBE	R			DATE	NAME	CLASS	SUBCLASS	FILING DA	
	VA	6	0	2	4	9	.8	2	02/15/2000	Oshlack et al.	424	476		
	VB	6	0	6	8	8	5_	5	05/30/2000	Leslie et al.	424	468		
	VC	6	0_	7	7	5	3	2	06/20/2000	Malkowska et al.	424	457		
	VD	6	0	7	7	5	3	3	06/20/2000	Oshlack et al.	424	461		
	VE	6	1	0	3	2	5	8	08/15/2000	Simon	424	449		
	VF	6	1	0	3	2	6	1	08/15/2000	Chasin et al.	424	459		
	VG	6	1	4	3	3_	2	2	11/07/2000	Sackler et al	424	459		
							F	OREI	GN PATENT D	OCUMENTS				
	DOCUMENT NUMBER DATE								DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
	VH													
	VI													
	VJ													
	VK													
	VL													
		•		,	ОТНЕ	R PRIC	OR AR	T (Incl	luding Author, 7	Γitle, Date, Pertinent P	ages, Etc.)			
	VM				, , , , , ,									
	VN									·				
	vo										_			
	VP											-		
	VQ													
	VR													
	vs													
EXAMINER		•		<u>-</u>				DATE CONSIDERED						
*EXAMINER: considered. Inc	Initial if	referen	ice con	sidered	d, whet	her or	not cit	ation is	s in conformanc	e with MPEP 609; Dr	aw line throug	gh citation if not i	n conformanc	e and not

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (REV. 7-80) PATENT AND TRADEMARK OFFICE										ATTY. DOCKET NO.: SERIAL NO.: 10/694,559				
	LIST C	F PR	IOR A	RT CI	TED I	BY AF	PLIC	APPLICANT(S): Robert F. KAIKO et al.						
	(Us	se seve	ral she	ets if n	ecessa	ry) 		FILING DATE: GROUP: 1615						
								UMENTS						
*EXAMINER INITIAL		DO	CUME	NT NU	ЈМВЕ	R			DATE	NAME	CLASS	·SUBCLASS	FILING DA IF APPROP	
	WA	6	1	4	3	3_	2	8	11/07/2000	Heafield et al.	424	489		
	WB	6	1	6	2	4	6	7	12/19/2000	Miller et al.	424	468		
	wc	6_	2_	1	0	7	1	4_	04/03/2001	Oshlack et al.	424	476		
	WD	6	2	7	0	8	6	3	05/08/2001	Palermo et al.	514	282		
	WE	6	2	5	4	8_	8	7	07/03/2001	Miller et al.	424	468		
	WF	6	2	6	1	5	9	9	07/17/2001	Oshlack et al.	424	457		
	WG	6	2	7	7	3	8	4_	08/21/2001	Kaiko et al.	424	400		
]	FORE	IGN P/TENT DO	OCUMENTS	· · ·			
		DO	CUME	NT N	JMBE	R			DATE	COUNTRY	CLASS	SUBCLASS	TRANSLA	TION
												YES	NO	
	WH													
	WL													
	WJ		:											
	wĸ													
	WL													
					OTHE	R PRIO	OR AR	T (Inc	luding Author,	Γitle, Date, Pertinent	Pages, Etc.)	•		
	WM													
	WN													
	wo													
	WP													
	wQ													
	WF													
	ws												·	
EXAMINER								DATE CONSIDERED						
*EXAMINER:	Initial if	referen	ice con	sidered	l, whet	her or	not cit	ation i	s in conformanc	e with MPEP 609; D	raw line throu	gh citation if not i	n conformance	e and not

FORM PTO-14- (REV. 7-80)	49								COMMERCE ARK OFFICE	ATTY. DOCKET NO.: SERIAL NO.: 10/694,559					
LIST OF PRIOR ART CITED BY APPLICANT										APPLICANT(S): Robert F. KAIKO et al.					
	(Us	se sevei	al she	ets if n	ecessa	ry)		FILING DATE: October 27, 2003		GROUP: 1615					
								U.S.	PATENT DOC	UMENTS					
*EXAMINER INITIAL		DOG	CUME	NT NI	JMBE	R			DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE		
	XA	6	2	9	4	1	9	5	09/25/2001	Oshlack et al.	424	457			
	XB	6	3	0	6	4	3	8	10/23/2001	Oshlack et al.	424	468			
	XC	6	3	2	6_	0	2	7	12/04/2001	Miller et al.	424	468			
	XD	6	3	3	_5	0	3	3	01/01/2002	Oshlack et al.	424	457			
	XC	6	3	7	5	9	5	7	04/23/2002	Kaiko et al.	424	400			
	ХF	6	3	8	7	4	0	4	05/14/2002	Oshlack et al.	424	480			
	XG	6	3	9	9	4	9	4	06/04/2002	Miller et al.	424	400			
	хн	6	4	7	5	4	9	4	11/05/2002	Kaiko et al.	424	400			
	ΧI	6	6	2	7	0	3	5	09/30/2003	Palermo, et al.	514	282			
	ХJ	6	7	1	6	4	4	9	04/06/2004	Oshlack, et al.	424	449			
	XK	6	6	9	6	0	8_	8	02/24/2004	Oshlack et al.	424	465			
	XL	6	6	9	6	0	6	6	02/24/2004	Kaiko et al.	424	400			
FOREIGN PAT	ENT DO	CUMF	NTS												
	ХМ														
	<u> </u>				OTHE	R PRIO	OR AR	T (Inc	luding Author.	Γitle, Date, Pertinent F	ages, Etc.)	· · · · · · · · · · · · · · · · · · ·			
	XN														
	хо					-									
	XP										Same and	· · · · · · · · · · · · · · · · · · ·	-		
	XQ														
	XR														
	xs														
	XT														
EXAMINER										DATE CONSIDERED					
*EXAMINER: considered. Inc										e with MPEP 609; Dr	aw line throu	gh citation if not i	n conformance and not		